Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
As of close of business last night, Humacyte Inc’s stock clocked out at $2.31, down -7.97% from its previous closing price of $2.51. In other words, the price has decreased by -$7.97 from its previous closing price. On the day, 4.22 million shares were traded. HUMA stock price reached its highest trading level at $2.4753 during the session, while it also had its lowest trading level at $2.25.
Ratios:
To gain a deeper understanding of HUMA’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.28 and its Current Ratio is at 3.68. In the meantime, Its Debt-to-Equity ratio is 2.28 whereas as Long-Term Debt/Eq ratio is at 2.15.
On December 20, 2024, H.C. Wainwright reiterated its Buy rating and also lowered its target price recommendation from $12 to $15.
On December 11, 2023, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $6.H.C. Wainwright initiated its Buy rating on December 11, 2023, with a $6 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Apr 14 ’25 when Scheessele William John bought 6,493 shares for $1.54 per share. The transaction valued at 9,999 led to the insider holds 22,018 shares of the business.
Sander Dale A. bought 20,000 shares of HUMA for $30,600 on Apr 10 ’25. The CFO and Chief Corp. Deve. Off. now owns 40,600 shares after completing the transaction at $1.53 per share. On Apr 10 ’25, another insider, Parikh Shamik J, who serves as the Chief Medical Officer of the company, bought 7,500 shares for $1.55 each. As a result, the insider paid 11,625 and bolstered with 7,500 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HUMA now has a Market Capitalization of 358324896 and an Enterprise Value of 343863328. For the stock, the TTM Price-to-Sale (P/S) ratio is 689.08 while its Price-to-Book (P/B) ratio in mrq is 9.94. Its current Enterprise Value per Revenue stands at 665.113 whereas that against EBITDA is -3.314.
Stock Price History:
The Beta on a monthly basis for HUMA is 1.89, which has changed by -0.725 over the last 52 weeks, in comparison to a change of 0.1116153 over the same period for the S&P500. Over the past 52 weeks, HUMA has reached a high of $9.79, while it has fallen to a 52-week low of $1.15. The 50-Day Moving Average of the stock is 6.04%, while the 200-Day Moving Average is calculated to be -35.23%.
Shares Statistics:
It appears that HUMA traded 4.03M shares on average per day over the past three months and 4638340 shares per day over the past ten days. A total of 155.12M shares are outstanding, with a floating share count of 125.45M. Insiders hold about 19.13% of the company’s shares, while institutions hold 39.93% stake in the company. Shares short for HUMA as of 1749772800 were 28426146 with a Short Ratio of 7.60, compared to 1747267200 on 30350872. Therefore, it implies a Short% of Shares Outstanding of 28426146 and a Short% of Float of 21.100001.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
